Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 12,350

Document Document Title
WO/2011/088843A1
The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection.  
WO/2011/089602A2
The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageou...  
WO/2011/085544A1
Compounds which effectively remove tumor or cancer cell and their use for the treatment and prevention of tumor or cancer by making immune system find tumor or cancer cell are provided. In detail, by immune identifier of tumor or cancer ...  
WO/2011/082288A1
Exemplary embodiments of this invention encompass a method for purifying a low purity steviol glycoside composition. In particular, this invention relates to a method for purifying low purity steviol glycoside compositions to obtain subs...  
WO/2011/076625A1
The invention relates to a sweetener and to a method for the production thereof.  
WO/2011/078383A1
Provided is a liquid-crystal compound which is usable as a base for injections. The compound is an amphipathic compound represented by general formula (I), wherein X and Y each represents a hydrogen atom or X and Y in cooperation represe...  
WO/2011/073112A3
Compounds of the formula (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are hydrogen or a substituent as described in the specification, are useful for the prevention and treatment of bacterial infectio...  
WO/2011/073112A2
Compounds of the formula (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are hydrogen or a substituent as described in the specification, are useful for the prevention and treatment of bacterial infectio...  
WO/2011/070592A3
The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates ...  
WO/2011/066653A1
Salacinol and ponkoranol homologues, derivatives thereof and methods of synthesizing and using said homologies and derivatives. The derivatives include stereoisomers, de-O-sulfonated compounds and congeners of the naturally occurring hom...  
WO/2011/058245A1
The present invention relates to mannopyranoside-derived compounds and to the use thereof as medicaments, in particular in the treatment of cancer diseases, and also to the method for preparing same and to pharmaceutical compositions com...  
WO/2011/058245A8
The present invention relates to mannopyranoside-derived compounds and to the use thereof as medicaments, in particular in the treatment of cancer diseases, and also to the method for preparing same and to pharmaceutical compositions com...  
WO/2011/058661A1
Provided is a method for extracting isosaponarin at a high concentration from wasabi (Wasabia japonica) leaves. Also provided is a method for extracting a material for foods, drugs and cosmetics. Isosaponarin is extracted at a high conce...  
WO/2011/055231A3
The invention describes substantially pure rebaudioside A polymorphs and processes to prepare them.  
WO/2011/056834A3
Thermally stable anhydrous Rebaudioside D can be provided by methods disclosed here and has been found to be more soluble in aqueous solutions than the previously known non-anhydrous Rebaudioside D. This physical property makes the anhyd...  
WO/2011/056834A2
Thermally stable anhydrous Rebaudioside D can be provided by methods disclosed here and has been found to be more soluble in aqueous solutions than the previously known non-anhydrous Rebaudioside D. This physical property makes the anhyd...  
WO/2011/052919A2
The present invention relates to alpga-galactosylceramide derivatives, to the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a pharmaceutical composition for an immune adjuvant, containing the derivativ...  
WO/2011/051520A1
The present invention relates to novel triterpenic saponins from the saffron (Crocus sativus L.) corm, a composition that comprises said saponins, the use thereof as adjuvant substances in protein vaccines, and also in the production of ...  
WO/2011/052919A3
The present invention relates to alpga-galactosylceramide derivatives, to the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a pharmaceutical composition for an immune adjuvant, containing the derivativ...  
WO/2011/048148A2
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...  
WO/2011/048148A3
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...  
WO/2011/044751A1
Foliamangiferosides having the general formula (I) are disclosed, wherein R is H or -OCH3. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds ...  
WO/2011/046057A1
Provided is a novel and non-natural sialic acid-containing sugar chain compound, which has a binding activity to a viral particle and remains stable even in the presence of sialidase, obtained by using a reaction with the use of a glycos...  
WO/2011/044498A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044538A1
Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are...  
WO/2011/044498A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044503A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044503A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...  
WO/2011/044501A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defin...  
WO/2011/044502A1
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. ...  
WO/2011/044502A9
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. ...  
WO/2011/044501A2
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defin...  
WO/2011/044538A9
Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are...  
WO/2011/044501A3
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defin...  
WO/2011/039107A1
The invention relates to a method for the preparation for a crystalline form of 1-chloro-4-(Β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofura n-3-yloxy)-benzyl]-benzene. In addition the invention relates to a crystalline form obtainable b...  
WO/2011/038356A2
This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilo triacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with ...  
WO/2011/035518A1
Pyrimidine derivatives and analogs, their pharmaceutically acceptable salts, processes for preparing them, pharmaceutical compositions comprising them, and their use in manufacture of medicaments for treating inflammatory and infectious ...  
WO/2011/029576A1
The present invention relates to a form of crystalline 4'-epidaunorubicin hydrochloride which is stable and readily soluble, and to a process for the production thereof. This process comprises crystallizing 4'-epidaunorubicin hydrochlori...  
WO/2011/025286A2
The present invention relates to lipoteichoic acid-derived glycolipids, and to pharmaceutical, food or cosmetic compositions and vaccine adjuvants comprising same. The lipoteichoic acid-derived glycolipids according to the present invent...  
WO/2011/025286A3
The present invention relates to lipoteichoic acid-derived glycolipids, and to pharmaceutical, food or cosmetic compositions and vaccine adjuvants comprising same. The lipoteichoic acid-derived glycolipids according to the present invent...  
WO/2011/017998A1
Gambogic acid cyclization analogues with formula I, II and III are disclosed, wherein cycles A, B and C are saturated or unsaturated alicyclic, alicyclic heterocyclic, aromatic ring or aromatic heterocyclic groups containing 4-10 members...  
WO/2011/019419A1
Tumors can be selectively targeted via compounds provided herein according to the formula, or a pharmaceutically acceptable salt thereof, wherein RA and RB are as defined herein. Tumors can be imaged or targeted for therapeutic treatment...  
WO/2011/018587A3
The invention relates to FGF receptor-activating N-sulfate oligosaccharides having Formula (I), wherein R1, R4, R6, and R8 are -OSO3- or hydroxyl groups, R2 is an -O-alkyl group or a monosaccharide having Formula (II), R3 is a disacchari...  
WO/2011/018588A3
The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3- or hydroxyl group, R3 is an alkyl, c...  
WO/2011/016558A1
Disclosed is a method for easily and economically producing a highly pure glucosylceramide-containing material in a large amount from a plant material. A highly pure glucosylceramide can be obtained in a large amount by a method for prod...  
WO/2011/009987A3
Aureolic acid derivatives, the method for preparation thereof and the uses thereof. The present invention provides a bacterial strain that produces compounds belonging to the aureolic acid family, which can be used in the treatment of ca...  
WO/2011/006237A1
Compounds of structural formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza are provided Pharmaceutical preparations thereof and methods for their preparation are also described. The thera...  
WO/2011/003876A1
Herein arc disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates arc useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues pr...  
WO/2011/000721A1
The present invention finds application in the field of medicine and, in particular, it relates to new compounds for the treatment and/or prevention of HIV; Ebola, Dengue, Hepatitis C, SARS or tuberculosis infections.  
WO/2010/149326A1
The present invention relates to a compound comprising an imine bond as an acid- labile trigger group, the use of such an imine bond as an acid-labile trigger group, a process of cleaving the imine bond in said compound, and a pharmaceut...  

Matches 451 - 500 out of 12,350